Skip to main content
PLOS One logoLink to PLOS One
. 2021 Apr 21;16(4):e0245415. doi: 10.1371/journal.pone.0245415

Spatial clustering of CD68+ tumor associated macrophages with tumor cells is associated with worse overall survival in metastatic clear cell renal cell carcinoma

Nicholas H Chakiryan 1,*, Gregory J Kimmel 2, Youngchul Kim 3, Ali Hajiran 1, Ahmet M Aydin 1, Logan Zemp 1, Esther Katende 1, Jonathan Nguyen 4, Neale Lopez-Blanco 4, Jad Chahoud 1, Philippe E Spiess 1, Michelle Fournier 1, Jasreman Dhillon 4, Liang Wang 5, Carlos Moran-Segura 4, Asmaa El-Kenawi 6, James Mulé 6, Philipp M Altrock 2, Brandon J Manley 1
Editor: Pankaj K Singh7
PMCID: PMC8059840  PMID: 33882057

Abstract

Immune infiltration is typically quantified using cellular density, not accounting for cellular clustering. Tumor-associated macrophages (TAM) activate oncogenic signaling through paracrine interactions with tumor cells, which may be better reflected by local cellular clustering than global density metrics. Using multiplex immunohistochemistry and digital pathologic analysis we quantified cellular density and cellular clustering for myeloid cell markers in 129 regions of interest from 55 samples from 35 patients with metastatic ccRCC. CD68+ cells were found to be clustered with tumor cells and dispersed from stromal cells, while CD163+ and CD206+ cells were found to be clustered with stromal cells and dispersed from tumor cells. CD68+ density was not associated with OS, while high tumor/CD68+ cell clustering was associated with significantly worse OS. These novel findings would not have been identified if immune infiltrate was assessed using cellular density alone, highlighting the importance of including spatial analysis in studies of immune cell infiltration of tumors.

Significance: Increased clustering of CD68+ TAMs and tumor cells was associated with worse overall survival for patients with metastatic ccRCC. This effect would not have been identified if immune infiltrate was assessed using cell density alone, highlighting the importance of including spatial analysis in studies of immune cell infiltration of tumors.

Introduction

Immune cell infiltration is typically quantified using cell density, which does not account for the local clustering of immune cells within the tumor-immune microenvironment (TIME). Localized cellular clustering of immune cells in the TIME is a seldom-used metric in studies of immune infiltration of tumors, but when applied has yielded novel and impactful findings across a variety of primary tumor sites and immune cell types [17].

Tumor-associated macrophages (TAM) activate oncogenic signaling and facilitate tumor growth and progression by secreting cytokines, growth factors, and angiogenic mediators, as well as a variety of proteases that activate additional growth factors and angiogenic mediators embedded in the extracellular matrix [714]. These paracrine interactions are concentration-gradient-dependent, and as such, the underlying biology may be better reflected by measures of local cellular clustering as opposed to global density metrics. Prior work has demonstrated an association between TAM density and worse overall survival (OS) in patients with clear cell renal cell carcinoma (ccRCC), but none have assessed TAM cellular clustering [9, 12, 14, 15].

Our primary objective was to determine whether cellular clustering of TAMs and tumor cells at the tumor/stromal interface was associated with worse OS for patients with metastatic ccRCC. The secondary objective was to describe the relative affinity for TAMs to be located in either the tumor or stromal compartments within the TIME.

Methods

Patient selection and specimen collection

We obtained 55 primary and metastatic tumor samples from 35 patients with metastatic ccRCC. For patients with multiple samples (N = 13), only the primary tumor sample was considered for the survival analysis. This study was reviewed and approved by the Advarra institutional review board (H. Lee Moffitt Cancer Center and Research Institute’s Total Cancer Care protocol MCC# 14690; Advarra IRB Pro00014441). Written informed consents were obtained from all tissue donors. Patients were included in this study if they (1) were diagnosed with metastatic ccRCC; (2) provided written consent to analysis of their tissue; and (3) did not receive any systemic therapy prior to initial tissue collection.

Multiplex immunofluorescent tissue staining

To prepare the tissue blocks, an experienced genitourinary pathologist (JD) reviewed each formalin fixed paraffin-embedded tissue sample and annotated 3 separate ROIs from the tumor-stroma-interface. The tumor-stroma-interface ROIs were selected such that each ROI contained approximately 50% tumor cells and 50% adjacent stroma, as to determine the relative affinity for myeloid cells to cluster into the tumor or stroma compartment. Tissue samples were then stained using the PerkinElmer OPAL 7 Color Automation Immunohistochemistry Kit (PerkinElmer, Waltham, MA) on the BOND RX Autostainer (Leica Biosystems, Vista, CA). In brief, tissue slides were sequentially stained using antibodies targeting CD68, CD163, and CD206. These markers were selected for their previously demonstrated frequency and impact in TAM studies in ccRCC. All subsequent steps, including deparaffinization, antigen retrieval, and staining, were performed using the OPAL manufacturer’s protocol. Pan-cytokeratin and 4′,6-diamidino-2-phenylindole (DAPI) counterstaining were applied to all slides, and imaging was performed using the Vectra3 Automated Quantitative Pathology Imaging System (PerkinElmer, Waltham, MA).

Quantitative image analysis

Multi-layer TIFF images were exported from InForm (PerkinElmer) and loaded into HALO 121 (Indica Labs, New Mexico) for quantitative image analyses. The size of the ROIs was standardized at 1356 × 1012 pixels, with a resolution of 0.5 μm/pixel, for a total surface area of 0.343 mm2. For each staining marker, a positivity threshold within the nucleus or cytoplasm was set by an experienced digital image analysist (JN), and the entire image set was analyzed. The generated data included the total cell count, positive cell counts of each IF marker, fluorescence intensity of every individual cell, Cartesian coordinates for each cell, and the percent of cells that were positive for each marker.

Spatial analysis

Cellular density was calculated globally for each ROI and defined as the number of cells per mm2. ROIs containing ≥10 cells positive for a relevant marker were considered eligible for spatial analysis. As there is no previously validated standard for this cutoff, the ≥10 cell cutoff was agreed upon through consensus of the authors. Cellular clustering was quantified using the Ripley’s K function, a methodology for quantifying spatial heterogeneity most commonly utilized in ecology, with isotropic edge correction, with the following normalization applied: nK(r) = K(r) / πr2, as described previously [1618] (Fig 1). As such, the expected value of nK(r) for all radii is 1.0, with values >1.0 representing cellular clustering, and values <1.0 representing cellular dispersion. The range of possible values for nK(r) is 0 to infinity. The nK(r) value is an observed over expected ratio (i.e. Tumor/CD68+ nK(25) = 1.30 can be interpreted as: “There were 30% more CD68+ cells observed within a 25um radius of each tumor cell than would be expected if the cells were randomly distributed.”). To reflect cellular clustering at a localized distance, nK(r) at a radius of 25um was utilized in this analysis and will henceforth be referred to as nK(25). The search-circle radius value of 25um was selected as it represents approximately double that of a typical ccRCC tumor cell radius, and as such should represent the area in the immediate vicinity of the cell. Examples of point pattern plots with high or low CD68+ density and tumor/CD68+ clustering, as measured by nK(25), are provided in Fig 2B.

Fig 1. Ripley’s K function.

Fig 1

A: Illustrative representation of the pairwise Ripley’s K function, where the number of cells of interest is identified within a search radius from another cell type, repeating the process over a continuum of radii, for each cell in the study area. B: The Ripley’s K function estimator, where n is the total number of points in the study area, W is the study area, 1{|xi-xj|}≤r} is an indicator worth a value of 1 if points i and j are within distance r, and c(xi,xj;r) represents the applied edge correction (this analysis utilized isotropic edge correction). C: Plot of the naïve K(r) function using a representative slide from our analysis. The black solid line is the observed K(r), and dotted red line is the expected distribution if cells were randomly distributed, assuming a Poisson distribution. D: Normalization of the naïve Ripley’s K function into K(r)/πr2, resulting in an expected distribution of 1 for all values of r. The search radius utilized in this analysis was 25um. In this manuscript, K(25um)/πr2 is abbreviated to “nK(25)”.

Fig 2.

Fig 2

A: Project workflow, in brief. IHC staining for myeloid markers (CD68, CD163, CD206) and PD-L1. Digital pathologic analysis is utilized to convert IHC slides to point pattern plots, which are then utilized to calculate measures of spatial heterogeneity. B: Examples of point pattern plots demonstrating high or low CD68+ cell density (cells/mm2; cut-point = 151.273), and high or low Tumor/CD68+ cell clustering (nK(25), cut-point = 1.30).

Statistical analysis

Spearman’s correlation coefficient was determined for CD68+ cell density and CD68+/tumor cell clustering, to determine the relationship between cell density and cell clustering. Pairwise nK(25) values were generated for each marker type as they related to tumor and stromal cells, for each ROI. These pairwise nK(25) values, per ROI, were compared within each marker type using Wilcoxon signed-rank testing. OS was defined using time from sample collection to death or censoring at last follow-up. Cell density and nK(25) cut-points for cohort stratification were determined using optimal cut-point methodology, minimizing the log-rank p-value for OS, as previously described [19]. Multivariable Cox regression was used to determine associations with OS, using age and International Metastatic RCC Database Consortium (IMDC) risk score as covariates [20]. A post-hoc power analysis was conducted to assess the minimum detectable hazard ratio for the Cox model. Statistical significance was defined as two-tailed p<0.05. Statistical analyses were performed using R program version 4.0.2 (Vienna, Austria), and spatial analysis was performed using the “spatstat” package [21].

Results

Patient characteristics

35 patients with metastatic ccRCC met criteria for inclusion. The median patient age was 58 (IQR 53–65), median primary tumor size was 8.0cm (IQR 6.0–10.3), 24 patients (69%) were male, 31 (89%) had a primary tumor grade of 3 or higher, and all patients were IMDC risk score 1 or greater (Table 1).

Table 1. Baseline patient characteristics at the time of sample collection.

Characteristic N = 351
Age (yrs) 58 (53, 65)
IMDC
  1 13 (37%)
  2 17 (49%)
  3+ 5 (14%)
Gender
  Female 11 (31%)
  Male 24 (69%)
Tumor Grade
  2 4 (11%)
  3 21 (60%)
  4 10 (29%)
Primary Tumor Size (cm) 8.0 (6.0, 10.3)

1 Statistics presented: median (IQR); n (%)

From the 55 samples obtained from this cohort, 129 ROIs were analyzed from the tumor/stroma interface.

TAM cellular density and TAM/tumor cell clustering metrics are poorly correlated

Cellular density (cells/mm2) and clustering (nK(25)) metrics were determined, as detailed in the methodology (Figs 1 and 2). The Spearman’s correlation coefficient for CD68+ cell density and tumor/CD68+ nK(25) indicated a weak negative correlation (R = -0.19, p = 0.046). This finding confirms that the cellular density and clustering metrics are not redundant (Fig 3A) within our cohort.

Fig 3.

Fig 3

A: Scatter plot and Spearman’s correlation of CD68+ cell density (cells/mm2) and Tumor/CD68+ (nK(25)), per ROI (N = 129, r = -0.19, p = 0.046). B: Boxplot diagrams of Ripley’s nK(25) values for Tumor/CD68+, Stroma/CD68+, Tumor/CD163+, Stroma/CD163+, Tumor/CD206+, Stroma/CD206+, Tumor/PDL1+, and Stroma/PDL1+, for all ROIs (N = 129). nK(25) values > 1 indicate cellular clustering, and values <1 indicate cellular dispersion. Asterix in plot title denotes Wilcoxon test p<0.05. C: Multivariable Cox regression for OS, using CD68+ cellular density and Tumor/CD68+ nK(25) as separate covariates, with associated KM estimates for high versus low Tumor/CD68+ nK(25). D: Multivariable Cox regression for OS, stratifying patients who had high CD68+ cellular density and high Tumor/CD68+ nK(25) versus other patients, with associated KM estimates.

TAMs have distinct affinities for the tumor and stromal compartments based on marker type

CD68+ TAMs were found to be clustered with tumor cells and dispersed from stromal cells (nK(25) = 1.10 and 0.90, respectively, p<0.01). TAMs expressing M2-phenotype markers CD163+ or CD206+ were found to be dispersed from tumor cells, and clustered with stromal cells (CD163: nK(25) = 0.77 and 1.15, respectively, p<0.01; CD206: nK(25) = 0.70 and 1.17, respectively, p<0.01). PD-L1+ cells did not demonstrate statistically significant spatial differences regarding their clustering with tumor and stromal cells (nK(25) = 0.78 and 0.72, respectively, p = 0.4) (Fig 3B). These findings suggest that TAMs may have varying biologic affinity for the tumor and stromal compartments based on their polarization phenotype.

High CD68+ TAM/tumor cellular clustering is associated with worse overall survival

Multivariable Cox regression analysis revealed that high CD68+ cell density was not associated with OS (HR = 1.68, 95%CI 0.48–22.8, p = 0.2), while high tumor/CD68+ clustering was associated with significantly worse OS (HR = 6.19, 95%CI 1.16–33.1, p = 0.033) (Fig 3C). After stratifying for both cell density and cell clustering, patients with high CD68+ density and high tumor/CD68+ clustering were found to have significantly worse OS (HR = 8.50, 95%CI 1.97–36.7, p = 0.004) (Fig 3D).

A post-hoc power analysis using a power of 0.80, alpha of 0.05, and event probability of 80% demonstrated that with our 35-patient cohort the Cox model would be adequate to detect a minimum detectable hazard ratio of 1.7 for a standardized continuous variable in a univariable Cox proportional hazards regression analysis.

High CD163+ TAM density is associated with worse overall survival

A robust survival analysis using CD163+ and CD206+ cell clustering was precluded by low populations of patients eligible for spatial analysis using these markers (N = 10 and N = 2, respectively) due to low cell counts. Multivariable Cox regression using CD163+ density, excluding clustering, revealed worse OS for patients with high CD163+ density (HR 19.4, 95%CI 3.6–105.0, p<0.001). CD206+ cell density was not associated with OS (HR 2.21, 95%CI 0.6–8.0, p = 0.2) (S1 Fig).

Discussion

Primarily, this analysis demonstrates the importance of performing spatial analysis when conducting investigations into immune cell infiltration of tumors. In this cohort, stratification by cellular density of CD68+ TAMs alone was insufficient to identify a survival difference. The addition of tumor/CD68+ cellular clustering was necessary to elucidate the clinical impact of CD68+ TAM infiltration. Furthermore, when CD68+ cell density and tumor/CD68+ cellular clustering were included as covariates in the same Cox regression, tumor/CD68+ clustering had a stronger association with OS (Fig 3C).

Measuring cellular clustering at a local level (25um) is a logical approach for assessing TAM infiltration, as their impact on tumor biology is via concentration-gradient-dependent effects occurring at close proximity. Thus, a localized clustering metric such as nK(25) would be expected to reflect the underlying biology of this interaction more so than a global metric such as cell density. To our knowledge, this is the first analysis to investigate the clinical impact of TAM clustering in ccRCC.

Secondarily, this analysis confirms previous work demonstrating the negative prognostic impact of TAM infiltration in ccRCC patients. It has been suggested that TAMs with an M2-like phenotype (markers CD163, CD204, and CD206) have a pro-tumor effect while M1-like TAMs (CD68, CD80, and CD86) may have an anti-tumor effect [13]. However, this simplified dichotomy may not hold for all primary tumor sites, as high CD68+ TAM density has been identified as a negative prognostic indicator in breast and gastric cancer [22, 23]. Similarly, our analysis identified high CD68+ TAM/tumor cell clustering as having a strong association with worse OS. Additionally, high CD163+ TAM cell density was associated with worse OS. Together, these findings suggest that high TAM infiltration may portend a worse prognosis in metastatic ccRCC regardless of M1/M2 polarization.

Additionally, this analysis identified that CD68+ TAMs tend to cluster with tumor cells and away from stromal cells, while CD163+ and CD206+ TAMs tend to cluster with stromal cells and away from tumor cells (Fig 3B). Interestingly, in a 2018 study using dynamic imaging microscopy to directly observe TAM and CD8+ T-cell interactions in squamous cell lung cancer, Peranzoni et al remarked as an aside that CD163+ and CD206+ TAMs could easily be found in the stroma, while TAMs in the tumor core seldom expressed these markers [24]. Our analysis notes a similar observation using quantifiable and reproducible metrics, potentially shedding light on a biologic affinity for M2 polarized TAMs to the stromal compartment of malignant tumors. Further biologic investigation of this association is needed.

Significant limitations to this analysis include the relatively small sample size (35 patients; 55 samples; 129 ROIs), and retrospective nature of the study. This relatively small population increases the risk of making Type-II errors in outcomes that were not reported as statistically significant. The post-hoc power analysis indicated a minimum detectable hazard ratio of 1.7 for a standard continuous variable in a univariable Cox proportional hazard regression analysis. As such, findings with hazard ratios below 1.7 are at risk for being false negative findings in this study. Additionally, these findings were not confirmed in a validation cohort, and certainly require prospective replication in larger cohorts. These findings certainly require prospective replication in larger cohorts. Additionally, this study did not investigate the potential biologic effects that TAMs exert on the TIME, and only assessed their spatial organization and heterogeneity. An inherent limitation to spatial analysis is that it is not feasible to reliably measure clustering when very few cells of interest are present in the ROI, resulting in several patients in our cohort being excluded from the survival analysis as it related to the clustering of relatively rare cell markers such as CD163 and CD206.

Conclusion

Overall, we identified the novel finding that CD68+ TAMs preferentially cluster into the tumor compartment at the tumor/stroma interface, that CD163+ and CD206+ TAMs preferentially cluster into the stromal compartment, and identified worse survival for metastatic ccRCC patients with increased spatial clustering of CD68+ TAMs and tumor cells. These findings highlight the importance of including spatial analysis in studies of immune infiltration of tumors.

Supporting information

S1 Fig. KM estimates and multivariable Cox regressions for OS, for CD163+ and CD206+ cell density using optimal cut-points (CD163+ = 130.349, CD206+ = 22.738), log-rank p values reported.

(TIF)

S1 Data

(CSV)

Data Availability

All relevant data are within the manuscript and its Supporting information files.

Funding Statement

This work was supported by the Urology Care Foundation Research Scholar Award Program and Society for Urologic Oncology (to BJM); the United States Army Medical Research Acquisition Activity Department of Defense (KC180139 to BJM); Total Cancer Care Protocol at Moffitt Cancer Center, which was enabled in part by the generous support of the DeBartolo Family; the Biostatistics and Bioinformatics Shared Resource at the H. Lee Moffitt Cancer Center & Research Institute, a National Cancer Institute designated Comprehensive Cancer Center (P30-CA076292); and the Tissue Core Facility at the H. Lee Moffitt Cancer Center & Research Institute (P30-CA076292). The content is solely the responsibility of the authors and does not necessarily represent the official views of the American Urological Association or the Urology Care Foundation.

References

  • 1.Carstens JL, Correa de Sampaio P, Yang D, et al. Spatial computation of intratumoral T cells correlates with survival of patients with pancreatic cancer. Nat Commun. 2017;8:15095. 10.1038/ncomms15095 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Heindl A, Sestak I, Naidoo K, Cuzick J, Dowsett M, Yuan Y. Relevance of Spatial Heterogeneity of Immune Infiltration for Predicting Risk of Recurrence After Endocrine Therapy of ER+ Breast Cancer. J Natl Cancer Inst. 2018;110(2). 10.1093/jnci/djx137 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Lundgren S, Elebro J, Heby M, et al. Quantitative, qualitative and spatial analysis of lymphocyte infiltration in periampullary and pancreatic adenocarcinoma. Int J Cancer. 2020;146(12):3461–3473. 10.1002/ijc.32945 [DOI] [PubMed] [Google Scholar]
  • 4.Carmona-Fontaine C, Deforet M, Akkari L, Thompson CB, Joyce JA, Xavier JB. Metabolic origins of spatial organization in the tumor microenvironment. Proc Natl Acad Sci U S A. 2017;114(11):2934–2939. 10.1073/pnas.1700600114 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Keren L, Bosse M, Marquez D, et al. A Structured Tumor-Immune Microenvironment in Triple Negative Breast Cancer Revealed by Multiplexed Ion Beam Imaging. Cell. 2018;174(6):1373–1387 e1319. 10.1016/j.cell.2018.08.039 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Schnotalle P, Koch K, Au-Yeung RKH, et al. T-Cell Clustering in Neoplastic Follicles of Follicular Lymphoma. Cancer Microenviron. 2018;11(2–3):135–140. 10.1007/s12307-018-0217-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Huang YK, Wang M, Sun Y, et al. Macrophage spatial heterogeneity in gastric cancer defined by multiplex immunohistochemistry. Nat Commun. 2019;10(1):3928. 10.1038/s41467-019-11788-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Akkari L, Gocheva V, Kester JC, et al. Distinct functions of macrophage-derived and cancer cell-derived cathepsin Z combine to promote tumor malignancy via interactions with the extracellular matrix. Genes Dev. 2014;28(19):2134–2150. 10.1101/gad.249599.114 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Kovaleva OV, Samoilova DV, Shitova MS, Gratchev A. Tumor Associated Macrophages in Kidney Cancer. Anal Cell Pathol (Amst). 2016;2016:9307549. 10.1155/2016/9307549 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Hu JM, Liu K, Liu JH, et al. CD163 as a marker of M2 macrophage, contribute to predicte aggressiveness and prognosis of Kazakh esophageal squamous cell carcinoma. Oncotarget. 2017;8(13):21526–21538. 10.18632/oncotarget.15630 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Lee C, Jeong H, Bae Y, et al. Targeting of M2-like tumor-associated macrophages with a melittin-based pro-apoptotic peptide. J Immunother Cancer. 2019;7(1):147. 10.1186/s40425-019-0610-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Muhitch JB, Hoffend NC, Azabdaftari G, et al. Tumor-associated macrophage expression of interferon regulatory Factor-8 (IRF8) is a predictor of progression and patient survival in renal cell carcinoma. J Immunother Cancer. 2019;7(1):155. 10.1186/s40425-019-0630-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Wu K, Lin K, Li X, et al. Redefining Tumor-Associated Macrophage Subpopulations and Functions in the Tumor Microenvironment. Front Immunol. 2020;11:1731. 10.3389/fimmu.2020.01731 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Cowman SJ, Fuja DG, Liu XD, et al. Macrophage HIF-1alpha Is an Independent Prognostic Indicator in Kidney Cancer. Clin Cancer Res. 2020;26(18):4970–4982. 10.1158/1078-0432.CCR-19-3890 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Chevrier S, Levine JH, Zanotelli VRT, et al. An Immune Atlas of Clear Cell Renal Cell Carcinoma. Cell. 2017;169(4):736–749 e718. 10.1016/j.cell.2017.04.016 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Marcon E, Puech F. A typology of distance-based measures of spatial concentration. Regional Science and Urban Economics. 2017;62:56–67. [Google Scholar]
  • 17.Ripley BD. Modelling Spatial Patterns. Journal of the Royal Statistical Society Series B (Methodological). 1977;39(2):172–212. [Google Scholar]
  • 18.Goreaud F, Pélissier R. On explicit formulas of edge effect correction for Ripley’s K-function. Journal of Vegetation Science. 1999;10(3):433–438. [Google Scholar]
  • 19.Faraggi D, Simon R. A simulation study of cross-validation for selecting an optimal cutpoint in univariate survival analysis. Stat Med. 1996;15(20):2203–2213. [DOI] [PubMed] [Google Scholar]
  • 20.Heng DY, Xie W, Regan MM, et al. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol. 2013;14(2):141–148. 10.1016/S1470-2045(12)70559-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Baddeley A, Turner R. spatstat: An R package for analyzing spatial point patterns. J Stat Softw. 2005;12(6):1–42. [Google Scholar]
  • 22.Su CY, Fu XL, Duan W, Yu PW, Zhao YL. High density of CD68+ tumor-associated macrophages predicts a poor prognosis in gastric cancer mediated by IL-6 expression. Oncol Lett. 2018;15(5):6217–6224. 10.3892/ol.2018.8119 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Yang J, Li X, Liu X, Liu Y. The role of tumor-associated macrophages in breast carcinoma invasion and metastasis. Int J Clin Exp Pathol. 2015;8(6):6656–6664. [PMC free article] [PubMed] [Google Scholar]
  • 24.Peranzoni E, Lemoine J, Vimeux L, et al. Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti-PD-1 treatment. Proc Natl Acad Sci U S A. 2018;115(17):E4041–E4050. 10.1073/pnas.1720948115 [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Pankaj K Singh

10 Feb 2021

PONE-D-20-39779

Spatial Clustering of CD68+ Tumor Associated Macrophages with Tumor Cells is Associated with Worse Overall Survival in Metastatic Clear Cell Renal Cell Carcinoma

PLOS ONE

Dear Dr. Chakiryan,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by 5th Aug 2021. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

We look forward to receiving your revised manuscript.

Kind regards,

Pankaj K Singh, Ph.D.

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Please include your table as part of your main manuscript and remove the individual file. Please note that supplementary tables should be uploaded as separate "supporting information" files.

3. Thank you for including your ethics statement: 

"All tumor samples were obtained through protocols approved by the institutional review board(H.Lee Moffitt Cancer Center and Research Institute’s Total Cancer Care protocol MCC#14690; Advarra IRB Pro00014441).Written informed consents were obtained from all tissue donors".   

a. Please amend your current ethics statement to confirm that your named institutional review board or ethics committee specifically approved this study.

b. Once you have amended this/these statement(s) in the Methods section of the manuscript, please add the same text to the “Ethics Statement” field of the submission form (via “Edit Submission”).

For additional information about PLOS ONE ethical requirements for human subjects research, please refer to http://journals.plos.org/plosone/s/submission-guidelines#loc-human-subjects-research

4. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions.

In your revised cover letter, please address the following prompts:

a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. Please see http://www.bmj.com/content/340/bmj.c181.long for guidelines on how to de-identify and prepare clinical data for publication. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories.

We will update your Data Availability statement on your behalf to reflect the information you provide.

5. Thank you for stating the following in the Competing Interests section:

'CONFLICT OF INTEREST DISCLOSURE

The corresponding author certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (ie. employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: NHC, GJK, AH, AMA, LZ, JN, JC, SF, MF, JD, SM, CM, EK, PMA, and YK have no disclosures; BJM is an NCCN Kidney Cancer Panel Member; PES is an NCCN Bladder and Penile Cancer Panel Member and Vice-Chair; JM is an Associate Center Director at Moffitt Cancer Center, has ownership interest in Fulgent Genetics, Inc., Aleta Biotherapeutics, Inc., Cold Genesys, Inc., Myst Pharma, Inc., and Tailored Therapeutics, Inc., and is a consultant/advisory board member for ONCoPEP, Inc., Cold Genesys, Inc., Morphogenesis, Inc., Mersana Therapeutics, Inc., GammaDelta Therapeutics, Ltd., Myst Pharma, Inc., Tailored Therapeutics, Inc., Verseau Therapeutics, Inc., Iovance Biotherapeutics, Inc., Vault Pharma, Inc., Noble Life Sciences Partners, Fulgent Genetics, Inc., UbiVac, LLC, Vycellix, Inc., and Aleta Biotherapeutics, Inc.'

a. Please confirm that this does not alter your adherence to all PLOS ONE policies on sharing data and materials, by including the following statement: "This does not alter our adherence to  PLOS ONE policies on sharing data and materials.” (as detailed online in our guide for authors http://journals.plos.org/plosone/s/competing-interests).  If there are restrictions on sharing of data and/or materials, please state these.

Please note that we cannot proceed with consideration of your article until this information has been declared.

b. Please include your updated Competing Interests statement in your cover letter; we will change the online submission form on your behalf.

Please know it is PLOS ONE policy for corresponding authors to declare, on behalf of all authors, all potential competing interests for the purposes of transparency. PLOS defines a competing interest as anything that interferes with, or could reasonably be perceived as interfering with, the full and objective presentation, peer review, editorial decision-making, or publication of research or non-research articles submitted to one of the journals. Competing interests can be financial or non-financial, professional, or personal. Competing interests can arise in relationship to an organization or another person. Please follow this link to our website for more details on competing interests: http://journals.plos.org/plosone/s/competing-interests

6. Please amend your list of authors on the manuscript to ensure that each author is linked to an affiliation. Authors’ affiliations should reflect the institution where the work was done (if authors moved subsequently, you can also list the new affiliation stating “current affiliation:….” as necessary).

7. Please include a separate caption for each figure in your manuscript.

8. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: No

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The authors conducted a study aiming to assess cellular density and cellular clustering for myeloid cell markers in 129 regions of interest from 55 samples from 35 patients with metastatic ccRCC. CD68+ density was not associated with OS, while high tumor/CD68+ cell clustering was associated with significantly worse OS. I have some concerns on the study design and statistical analysis.

1. The authors need to provide the sample size calculation and power analysis to justify the design of the study.

2. The definition of overall survival is starting from the sample collection time which may varies across patients. The starting time is suggested to use either diagnosis time or treatment starting time.

3. Have authors conducted assessment to test the Cox proportional hazards assumption?

4. The major limitation of the study is that, there is no validation cohort of the study, it needs to be discussed in the manuscript.

Reviewer #2: In this manuscript by Chakriyan et. al., the authors have performed spatial clustering analysis of macrophage markers in metastatic clear cell renal cell carcinoma samples using multiplex immunohistochemistry. The authors have analyzed spatial clusters of macrophage markers with tumor and stromal sections of the tumor tissue to predict the effect on overall survival. It is an interesting approach to analyze and predict overall survival in patients. As mentioned by authors the main limitation of the study is small sample size. The authors show that CD68 spatial distribution has a role to play in predicting OS. The CD163 and CD206 are M2 macrophage markers and are also associated with worse OS in multiple cancer studies. The experimental data would have been more informative and relevant if public database-based OS were compared with the multiplex immunohistochemistry-based spatial clustering of markers. Overall, the article presents an interesting approach to predict overall OS based on spatial distribution of markers. The authors should address the concerns listed:

1. The authors should discuss the relevance of CD163 and CD206 marker clustering in the stromal regions. Since tumor cells secrete a variety of factors that polarize macrophages to M2 type, it is intriguing to note why M2 markers are localized in stromal compartment.

2. Have the authors checked the spatial distribution of CD80 and CD86? Is the staining pattern distribution of these markers similar to CD68?

3. In the Figure 2, authors have stained the tissues for PD-L1 also. The authors should describe the PD-L1 expression in results.

4. Did the authors observe any difference in spatial distribution of CD68 in tissues when segregated based on gender and does it have any effect on OS also?

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2021 Apr 21;16(4):e0245415. doi: 10.1371/journal.pone.0245415.r002

Author response to Decision Letter 0


26 Feb 2021

NOTE: The response to reviewers is also included as an attached file, which includes an appendix with supporting information to accompany the responses.

RESPONSE TO REVIEWERS

We would like to thank the reviewers for their careful reading of the manuscript and thoughtful feedback.

Reviewer #1: The authors conducted a study aiming to assess cellular density and cellular clustering for myeloid cell markers in 129 regions of interest from 55 samples from 35 patients with metastatic ccRCC. CD68+ density was not associated with OS, while high tumor/CD68+ cell clustering was associated with significantly worse OS. I have some concerns on the study design and statistical analysis.

1. The authors need to provide the sample size calculation and power analysis to justify the design of the study.

This study was conceived as a pilot feasibility study to explore the effect of TAM/tumor spatial clustering on overall survival, a relationship that has not been previously assessed. As such, our study design was not based on an explicit statistical hypothesis but we were interested in discovering large effect sizes. A power/sample size analysis using a power of 0.80, and alpha of 0.05, with an 80% event rate indicates that the 35-patient cohort in our analysis would be adequate to detect a minimum detectable hazard ratio (MDHR) of 1.7 for a standardized continuous variable in a univariate Cox proportional hazards regression analysis. This has been included in the methods, results, and discussion sections of the manuscript (lines 143 to 144, and 181 to 184).

We consider this MDHR to be appropriate, as we were interested in discovering large effect sizes. We certainly acknowledge that with a small cohort we are at risk of making Type-II errors in outcomes which were not reported as significant in the manuscript. This limitation has been added to the discussion section of the manuscript (lines 223 to 227).

2. The definition of overall survival is starting from the sample collection time which may varies across patients. The starting time is suggested to use either diagnosis time or treatment starting time.

We explicitly chose OS from the time of sample collection when the study was designed. The specific variables of interest in this study were immune cell clustering and density, which are identified in a snapshot that occurs exactly at the time of sample collection. As such, this reflects survival from the moment in time that these variables were measured, which we feel is the appropriate timeframe.

Additionally, all samples included in this study were collected in the brief pre-treatment window from patients with metastatic ccRCC, and thus the time from diagnosis to sample collection is very short. The median time from diagnosis to sample collection was 26 days (IQR 9 – 42).

3. Have authors conducted assessment to test the Cox proportional hazards assumption?

We have included an assessment of the Cox proportional hazards assumption of the primary Cox regression model (Figure 3C). None of the individual covariates or the Schoenfeld’s global chi-square test violated the proportional hazards assumption. This is included at the bottom of this file as an Appendix.

4. The major limitation of the study is that, there is no validation cohort of the study, it needs to be discussed in the manuscript.

We agree completely. This analysis certainly warrants prospective validation in a larger cohort. We have added this into the limitations section (lines 227 to 228).

Reviewer #2: In this manuscript by Chakriyan et. al., the authors have performed spatial clustering analysis of macrophage markers in metastatic clear cell renal cell carcinoma samples using multiplex immunohistochemistry. The authors have analyzed spatial clusters of macrophage markers with tumor and stromal sections of the tumor tissue to predict the effect on overall survival. It is an interesting approach to analyze and predict overall survival in patients. As mentioned by authors the main limitation of the study is small sample size. The authors show that CD68 spatial distribution has a role to play in predicting OS. The CD163 and CD206 are M2 macrophage markers and are also associated with worse OS in multiple cancer studies. The experimental data would have been more informative and relevant if public database-based OS were compared with the multiplex immunohistochemistry-based spatial clustering of markers. Overall, the article presents an interesting approach to predict overall OS based on spatial distribution of markers. The authors should address the concerns listed:

1. The authors should discuss the relevance of CD163 and CD206 marker clustering in the stromal regions. Since tumor cells secrete a variety of factors that polarize macrophages to M2 type, it is intriguing to note why M2 markers are localized in stromal compartment.

We agree that this is a highly interesting finding. We do not have an answer as to why CD163+ and CD206+ TAMs preferentially cluster into the stromal compartment. However, it is worth noting that this relationship was remarked upon in a prior study, though it was not the purpose of that study and was not quantified (Reference #24 in the manuscript). Further work regarding macrophage chemotaxis into the tumor microenvironment is warranted. For our part, we will first pursue validation of these findings in a larger IF cohort, to confirm this association.

2. Have the authors checked the spatial distribution of CD80 and CD86? Is the staining pattern distribution of these markers similar to CD68?

This is an interesting question, but unfortunately the myeloid panel used in this study did not include the CD80 or CD86 markers.

3. In the Figure 2, authors have stained the tissues for PD-L1 also. The authors should describe the PD-L1 expression in results.

Thank you for noticing this discrepancy. We have included the PDL1 distribution results in the results section (lines 168 to 170).

4. Did the authors observe any difference in spatial distribution of CD68 in tissues when segregated based on gender and does it have any effect on OS also?

These are interesting questions. We have included this data below as an Appendix to this file. There was no difference in CD68/Tumor clustering or OS between genders in our cohort.

Attachment

Submitted filename: Response to reviewers.docx

Decision Letter 1

Pankaj K Singh

6 Apr 2021

Spatial Clustering of CD68+ Tumor Associated Macrophages with Tumor Cells is Associated with Worse Overall Survival in Metastatic Clear Cell Renal Cell Carcinoma

PONE-D-20-39779R1

Dear Dr. Chakiryan,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Pankaj K Singh, Ph.D.

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: (No Response)

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: (No Response)

Reviewer #2: The authors have addressed all the comments satisfactorily by either performing the experiments or providing justifications.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Wei Xu

Reviewer #2: No

Acceptance letter

Pankaj K Singh

8 Apr 2021

PONE-D-20-39779R1

Spatial Clustering of CD68+ Tumor Associated Macrophages with Tumor Cells is Associated with Worse Overall Survival in Metastatic Clear Cell Renal Cell Carcinoma

Dear Dr. Chakiryan:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Pankaj K Singh

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Fig. KM estimates and multivariable Cox regressions for OS, for CD163+ and CD206+ cell density using optimal cut-points (CD163+ = 130.349, CD206+ = 22.738), log-rank p values reported.

    (TIF)

    S1 Data

    (CSV)

    Attachment

    Submitted filename: Response to reviewers.docx

    Data Availability Statement

    All relevant data are within the manuscript and its Supporting information files.


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES